Fair balance, both ways.
Here, you’ll find copy that earns attention from patients and HCPs, and still clears medical, legal, and regulatory review.
At Grey, I was lead strategist and supervised copy on Pfizer and Lilly's pre-launch program for Raylumis (tanezumab), an NGF inhibitor for osteoarthritis pain, and led the creative effort behind the consumer journey work for Emergen-C. I worked side by side with medical writers, art directors and the rest of a multidisciplinary team, and took the Raylumis work through Pfizer's pre-medical review and Review Committee myself.
Brands: Raylumis (Pfizer and Lilly) · Emergen-C
Streams: Unbranded DTC · HCP · Now Approved DTC site · CRM · Consumer journey mapping
Review: Pfizer pre-medical review and Review Committee
Raylumis never made it to market (it didn't win FDA approval, and development ended in 2021), which happens in pharma more often than portfolios admit. Some are for internal use, other pieces were FPOs.
